Alzheimer's Disease
CNS 7 original drugsCNS indication. Alzheimer's Disease has 7 FDA-approved novel treatments, led by AVID RADIOPHARMS INC, with 386 active industry clinical trials across 10 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Alzheimer's Disease Market Leaders
Companies with the most FDA-approved novel Alzheimer's Disease drugs.
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q4 2026
KarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Estimated · aging NCT06126224
Q3 2027
KarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Estimated · aging NCT05980949
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Alzheimer's Disease Treatments by Mechanism
Top 8 mechanisms across 8 industry trials with a known mechanism of action.
Cholinesterase Inhibitor
1 trials 1 sponsor
GLP-1 Receptor Agonist
1 trials 1 sponsor
Atypical Antipsychotic
1 trials 1 sponsor
Orexin Receptor Antagonist
1 trials 1 sponsor
IL1R1
1 trials 1 sponsor
Retinoid
1 trials 1 sponsor
Phosphodiesterase 4 Inhibitor
1 trials 1 sponsor
Cardiac Glycoside
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Alzheimer's Disease Clinical Pipeline by Phase
752 industry-sponsored trials across 240 sponsors
Showing 27 of 27 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Alpha Cognition, Inc | Zunveyl® | — | RECRUITING | 2027-04 | NCT07633470 |
| Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | GV-971 | — | RECRUITING | 2029-06 | NCT05908695 |
| Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Sodium Oligomannate Capsules | — | ACTIVE NOT RECRUITING | 2025-01 | NCT05058040 |
| Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Sodium Oligomannate Capsules (GV-971) | — | ACTIVE NOT RECRUITING | 2025-01 | NCT05181475 |
| Eli Lilly | Donanemab | — | NOT YET RECRUITING | 2030-09 | NCT07838155 |
| Carnot Laboratories | Memantine | — | COMPLETED | 2025-08-12 | NCT07417670 |
| Novartis | Rivastigmine | Cholinesterase Inhibitor [EPC] | COMPLETED | 2022-12-07 | NCT02989402 |
| Dong-A ST Co., Ltd. | Acetyl-L-Carnitine | — | COMPLETED | 2018-09-29 | NCT02955706 |
| Novartis | Rivastigmine Patch | — | COMPLETED | 2018-05-07 | NCT02703636 |
| Lantheus Biosciences Ltd. | Neuraceq (florbetaben 18F) | — | COMPLETED | 2016-09 | NCT02681172 |
| Novartis | ENA713 | — | COMPLETED | 2015-09 | NCT01948791 |
| Eisai Korea Inc. | Donepezil HCL | — | COMPLETED | 2015-05 | NCT02097056 |
| Avid Radiopharmaceuticals | florbetapir (18F) | — | COMPLETED | 2015-04 | NCT01703702 |
| Avid Radiopharmaceuticals | florbetapir F 18 | — | COMPLETED | 2014-08 | NCT02051790 |
| Avid Radiopharmaceuticals | Florbetapir (18F) | — | COMPLETED | 2014-05 | NCT02107599 |
| Avid Radiopharmaceuticals | Florbetapir F18 | — | COMPLETED | 2014-04 | NCT01946243 |
| Novartis | Rivastigmine transdermal patch | — | COMPLETED | 2013-12 | NCT01529619 |
| Janssen Pharmaceutical K.K. | Galantamine | — | COMPLETED | 2013-06 | NCT01478633 |
| Novartis | Rivastigmine transdermal | — | COMPLETED | 2012-01 | NCT01047579 |
| Novartis | Rivastigmine 4.6 mg/24 h (5 cm^2) | — | COMPLETED | 2012-01 | NCT00948766 |
| Novartis | Rivastigmine transdermal patch | — | COMPLETED | 2011-10 | NCT00731224 |
| NeuroBioPharm Inc. | — | — | COMPLETED | 2010-07 | NCT00867828 |
| Novartis | Rivastigmine transdermal patch | — | COMPLETED | 2009-01 | NCT00622713 |
| Eisai Inc. | Donepezil HCl | — | COMPLETED | 2008-12 | NCT00571064 |
| Janssen-Cilag, S.A. | Galantamine | — | TERMINATED | 2011-06 | NCT01181921 |
| Merz Pharmaceuticals GmbH | Memantine | — | TERMINATED | 2009-05 | NCT00649220 |
| Eisai Inc. | Donepezil Hydrochloride (Aricept) | — | WITHDRAWN | 2009-06 | NCT00711204 |
Showing 100 of 155 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | KarXT | — | RECRUITING | 2026-11-24 | NCT06585787 |
| JYAMS PET Research & Development Limited | [18F]-APN-1607 | — | RECRUITING | 2026-12-01 | NCT07422857 |
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | KarXT | — | RECRUITING | 2026-12-09 | NCT06126224 |
| JYAMS PET Research & Development Limited | [18F]-APN-1607 | — | RECRUITING | 2027-04-30 | NCT07752784 |
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | KarXT | — | RECRUITING | 2027-09-07 | NCT05980949 |
| ACADIA Pharmaceuticals Inc. | ACP-204 | — | RECRUITING | 2028-01 | NCT06159673 |
| Bristol-Myers Squibb | KarXT | — | RECRUITING | 2028-02-21 | NCT06947941 |
| Lantheus Biosciences Ltd. | [18F]PI-2620 | — | RECRUITING | 2028-03 | NCT05641688 |
| CereMark Pharma, LLC | [F-18]Flornaptitril | — | RECRUITING | 2028-06-30 | NCT06254469 |
| Bristol-Myers Squibb | KarXT | — | RECRUITING | 2028-09-11 | NCT06976216 |
| Bristol-Myers Squibb | KarXT | — | RECRUITING | 2028-09-11 | NCT06976203 |
| Bristol-Myers Squibb | Xanomeline/Trospium Chloride Capsule | — | RECRUITING | 2028-11-03 | NCT07011745 |
| Bristol-Myers Squibb | Xanomeline/Trospium Chloride Capsule | — | RECRUITING | 2028-11-24 | NCT07011732 |
| Exciva GmbH | EXV-802 | — | RECRUITING | 2029-01 | NCT07284472 |
| Bristol-Myers Squibb | KarXT | — | RECRUITING | 2029-06-22 | NCT06937229 |
| Eli Lilly | Donanemab | — | RECRUITING | 2029-09 | NCT07602582 |
| Eli Lilly | Donanemab | — | RECRUITING | 2030-04 | NCT07571161 |
| Roche | Trontinemab | — | RECRUITING | 2032-07-30 | NCT07717411 |
| Eli Lilly | — | — | RECRUITING | 2033-07 | NCT07142954 |
| Roche | — | — | RECRUITING | 2035-07-31 | NCT07177352 |
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | KarXT | — | RECRUITING | 2026-10-05 | NCT05511363 |
| ScandiBio Therapeutics AB | Combined metabolic activators | — | RECRUITING | 2026-09 | NCT07062198 |
| Sinotau Pharmaceutical Group | XTR006 | — | RECRUITING | 2025-12-31 | NCT07115238 |
| Eisai Inc. | Lecanemab IV | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT03887455 |
| Eli Lilly | Donanemab | — | ACTIVE NOT RECRUITING | 2027-11 | NCT05026866 |
| Annovis Bio Inc. | buntanetap/posiphen | — | ACTIVE NOT RECRUITING | 2027-12 | NCT06709014 |
| Roche | Trontinemab | — | ACTIVE NOT RECRUITING | 2028-02-16 | NCT07170150 |
| Roche | Trontinemab | — | ACTIVE NOT RECRUITING | 2028-02-16 | NCT07169578 |
| Eli Lilly | Donanemab | — | ACTIVE NOT RECRUITING | 2028-05 | NCT05508789 |
| Eisai Inc. | Lecanemab | — | ACTIVE NOT RECRUITING | 2028-12-21 | NCT04468659 |
| Eli Lilly | Remternetug | — | ACTIVE NOT RECRUITING | 2029-04 | NCT06653153 |
| Actinogen Medical | Xanamem | — | ACTIVE NOT RECRUITING | 2026-09-22 | NCT06125951 |
| AriBio Co., Ltd. | AR1001 | — | ACTIVE NOT RECRUITING | 2026-06-29 | NCT05531526 |
| Sound Wave Innovation CO., LTD. | — | — | ACTIVE NOT RECRUITING | 2026-01-31 | NCT05983575 |
| Eli Lilly | Donanemab | — | ACTIVE NOT RECRUITING | 2024-05-16 | NCT05738486 |
| Eli Lilly | Donanemab | — | ACTIVE NOT RECRUITING | 2023-04-14 | NCT04437511 |
| Samsung Pharmaceutical Co., Ltd. | GV1001 1.12mg | — | NOT YET RECRUITING | 2028-01 | NCT05303701 |
| AB Science | Masitinib (4.5) | — | NOT YET RECRUITING | 2028-12 | NCT05564169 |
| Moleac Pte Ltd. | MLC 901 | — | NOT YET RECRUITING | 2029-02 | NCT07191028 |
| Cerecin | Tricaprilin | — | NOT YET RECRUITING | 2030-01 | NCT05809908 |
| T3D Therapeutics, Inc. | T3D-959 | — | NOT YET RECRUITING | 2031-04 | NCT06964230 |
| KeifeRx, LLC | Nilotinib BE 84mg | — | NOT YET RECRUITING | 2025-12-31 | NCT05143528 |
| Novo Nordisk | Semagludtide | — | COMPLETED | 2025-09-16 | NCT04777396 |
| Axsome Therapeutics, Inc. | AXS-05 (dextromethorphan-bupropion) | — | COMPLETED | 2024-12-03 | NCT04947553 |
| Axsome Therapeutics, Inc. | AXS-05 | — | COMPLETED | 2024-11-21 | NCT05557409 |
| Cassava Sciences, Inc. | Simufilam | — | COMPLETED | 2024-10-02 | NCT04994483 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2024-08-19 | NCT05891496 |
| LeonaBio | ATH-1017 | — | COMPLETED | 2024-07-15 | NCT04488419 |
| Anavex Life Sciences Corp. | ANAVEX2-73 | — | COMPLETED | 2024-06-14 | NCT04314934 |
| Alzheon Inc. | Experimental: ALZ-801 | — | COMPLETED | 2024-05-29 | NCT04770220 |
| Eli Lilly | Remternetug (IV) | — | COMPLETED | 2024-04-24 | NCT05463731 |
| Annovis Bio Inc. | Buntanetap/Posiphen | — | COMPLETED | 2024-02-13 | NCT05686044 |
| APRINOIA Therapeutics | [18F]APN-1607 | — | COMPLETED | 2023-12-25 | NCT05542953 |
| BioVie Inc. | NE3107 | — | COMPLETED | 2023-09-30 | NCT04669028 |
| Axsome Therapeutics, Inc. | AXS-05 | — | COMPLETED | 2022-11-21 | NCT04797715 |
| AgeneBio | AGB101 220 mg tablet | — | COMPLETED | 2022-11-02 | NCT03486938 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Brexpiprazole | Atypical Antipsychotic [EPC] | COMPLETED | 2022-09-19 | NCT03594123 |
| Eli Lilly | Donanemab | — | COMPLETED | 2022-09-09 | NCT05108922 |
| Anavex Life Sciences Corp. | High dose ANAVEX2-73 | — | COMPLETED | 2022-06-30 | NCT03790709 |
| TauRx Therapeutics Ltd | TRx0237 16 mg/day | — | COMPLETED | 2022-03-31 | NCT03446001 |
| Cortexyme Inc. | COR388 capsule | — | COMPLETED | 2022-01-01 | NCT03823404 |
| Roche | Gantenerumab | — | COMPLETED | 2021-04-16 | NCT02051608 |
| AB Science | Masitinib | — | COMPLETED | 2020-12 | NCT01872598 |
| AZTherapies, Inc. | ALZT-OP1a | — | COMPLETED | 2020-11-13 | NCT02547818 |
| Roche | Gantenerumab | — | COMPLETED | 2020-09-10 | NCT01224106 |
| Icure Pharmaceutical Inc. | Donepezil patch | — | COMPLETED | 2020-07-03 | NCT03197740 |
| Axsome Therapeutics, Inc. | AXS-05 | — | COMPLETED | 2020-04-17 | NCT03226522 |
| Avid Radiopharmaceuticals | flortaucipir F18 | — | COMPLETED | 2019-04-28 | NCT03901105 |
| Avid Radiopharmaceuticals | flortaucipir F 18 | — | COMPLETED | 2019-04-26 | NCT03901092 |
| Merck | Suvorexant | Orexin Receptor Antagonist [EPC] | COMPLETED | 2018-09-30 | NCT02750306 |
| Shanghai Greenvalley Pharmaceutical Co., Ltd. | Sodium oligo-mannurarate 900mg | — | COMPLETED | 2018-06-29 | NCT02293915 |
| Avid Radiopharmaceuticals | Flortaucipir F18 | — | COMPLETED | 2018-06-13 | NCT02516046 |
| Instituto Grifols, S.A. | Albumin 5% | — | COMPLETED | 2018-03-06 | NCT01561053 |
| Axovant Sciences Ltd. | RVT-101 | — | COMPLETED | 2017-09 | NCT02585934 |
| Avid Radiopharmaceuticals | florbetapir F 18 | — | COMPLETED | 2017-07-28 | NCT02016560 |
| H. Lundbeck A/S | Idalopirdine 60 mg | — | COMPLETED | 2017-07-06 | NCT02079246 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Brexpiprazole, OPC-34712 | — | COMPLETED | 2017-03-15 | NCT01862640 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Brexpiprazole, OPC-34712 | — | COMPLETED | 2017-03 | NCT01922258 |
| H. Lundbeck A/S | Idalopirdine | — | COMPLETED | 2017-01 | NCT02006654 |
| H. Lundbeck A/S | Idalopirdine | — | COMPLETED | 2016-12 | NCT02006641 |
| Cerecin | AC-1204 | — | COMPLETED | 2016-10-24 | NCT01741194 |
| H. Lundbeck A/S | Idalopirdine | — | COMPLETED | 2016-07 | NCT01955161 |
| TauRx Therapeutics Ltd | TRx0237 200 mg/day | — | COMPLETED | 2016-05 | NCT01689233 |
| TauRx Therapeutics Ltd | TRx0237 150 mg/day | — | COMPLETED | 2015-11 | NCT01689246 |
| Novartis | Active Comparator | — | COMPLETED | 2014-05 | NCT01614886 |
| GE Healthcare | Flutemetamol (18F) Injection | — | COMPLETED | 2014-01 | NCT01028053 |
| SK Chemicals Co., Ltd. | SK-PC-B70M | — | COMPLETED | 2013-08 | NCT01249196 |
| Novartis | Rivastigmine Patch | — | COMPLETED | 2013-05 | NCT01399125 |
| Avid Radiopharmaceuticals | florbetapir (18F) | — | COMPLETED | 2013-02 | NCT01662882 |
| GE Healthcare | [18F]Flutemetamol | — | COMPLETED | 2012-08 | NCT01672827 |
| Eli Lilly | LY2062430 | — | COMPLETED | 2012-06 | NCT00904683 |
| Eli Lilly | LY2062430 | — | COMPLETED | 2012-04 | NCT00905372 |
| Medivation, Inc. | Dimebon | — | COMPLETED | 2011-12 | NCT00829374 |
| Life Molecular Imaging SA | Florbetaben (BAY94-9172) | — | COMPLETED | 2011-09 | NCT01020838 |
| Eli Lilly | LY450139 | — | COMPLETED | 2011-05 | NCT00594568 |
| Eli Lilly | LY450139 | — | COMPLETED | 2011-04 | NCT00762411 |
| Eli Lilly | semagacestat | — | COMPLETED | 2011-04 | NCT01035138 |
| Avid Radiopharmaceuticals | florbetapir F 18 | — | COMPLETED | 2011-03 | NCT01447719 |
| Avid Radiopharmaceuticals | florbetapir F 18 | — | COMPLETED | 2011-02 | NCT01565382 |
| Avid Radiopharmaceuticals | florbetapir F 18 | — | COMPLETED | 2010-03 | NCT00857415 |
Showing 100 of 285 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Ono Pharmaceutical Co., Ltd. | ONO-2020 | — | RECRUITING | 2026-12-31 | NCT06803823 |
| Excelsior | EX039 | — | RECRUITING | 2026-12-31 | NCT05413655 |
| Arrowhead Pharmaceuticals | ARO-MAPT-SC | — | RECRUITING | 2027-06 | NCT07221344 |
| Amydis Inc. | AMDX-2011P | — | RECRUITING | 2027-07 | NCT06514001 |
| Bristol-Myers Squibb | BMS-986368 | — | RECRUITING | 2027-11-26 | NCT06808984 |
| MapLight Therapeutics | ML-007C-MA | — | RECRUITING | 2027-12 | NCT06887192 |
| Halia Therapeutics, Inc. | HT-4253 | — | RECRUITING | 2028-02 | NCT07399171 |
| NKGen Biotech, Inc. | SNK01 | — | RECRUITING | 2028-03 | NCT06189963 |
| NKGen Biotech, Inc. | SNK01 | — | RECRUITING | 2028-04 | NCT07228078 |
| NewAmsterdam Pharma | Obicetrapib 10 mg | — | RECRUITING | 2028-09 | NCT07794670 |
| GSK | GSK4527226 | — | RECRUITING | 2028-09-15 | NCT07105709 |
| Intra-Cellular Therapies, Inc. | ITI-1284 | — | RECRUITING | 2028-09-30 | NCT06540833 |
| Shanghai Auzone Biological Technology Co., Ltd. | TTYP01 tables 60mg | — | RECRUITING | 2028-10-23 | NCT07252440 |
| Lighthouse Pharmaceuticals, Inc. | LHP588 | — | RECRUITING | 2029-01-31 | NCT06847321 |
| AC Immune SA | ACI-24.060 at Dose A in Study Part 1a | — | RECRUITING | 2029-04 | NCT05462106 |
| Merck | MK-2214 | — | RECRUITING | 2029-04-30 | NCT07033494 |
| Sanofi | SAR448851 | — | RECRUITING | 2029-07-31 | NCT07688213 |
| Roche | RO7568282 | — | RECRUITING | 2029-11-01 | NCT07781657 |
| Alnylam Pharmaceuticals | Mivelsiran | — | RECRUITING | 2030-05-18 | NCT07636811 |
| AbbVie | ABBV-1758 | — | RECRUITING | 2030-10 | NCT07599670 |
| NSC-Therapeutics | NSC001 | — | RECRUITING | 2026-07-30 | NCT06995573 |
| Ashvattha Therapeutics, Inc. | 18F-OP-801 | — | RECRUITING | 2026-01-01 | NCT05395624 |
| Roche | RO7269162 | — | ACTIVE NOT RECRUITING | 2026-11-19 | NCT06402838 |
| Eisai Inc. | E2814 | — | ACTIVE NOT RECRUITING | 2026-12-03 | NCT06602258 |
| Bristol-Myers Squibb | BMS-986446 | — | ACTIVE NOT RECRUITING | 2026-12-17 | NCT06268886 |
| Janssen Pharmaceutica N.V., Belgium | JNJ-64042056 | — | ACTIVE NOT RECRUITING | 2026-12-22 | NCT06544616 |
| Cognition Therapeutics | CT1812 | — | ACTIVE NOT RECRUITING | 2027-05-31 | NCT05531656 |
| Roche | RO7126209 | — | ACTIVE NOT RECRUITING | 2027-07-31 | NCT04639050 |
| Alzamend Neuro, Inc. | ALZN002 (autologous DCs pulsed with E22W mutant peptide). | — | ACTIVE NOT RECRUITING | 2028-03-03 | NCT05834296 |
| Novartis | VHB937 | — | ACTIVE NOT RECRUITING | 2028-09-14 | NCT07094516 |
| IGC Pharma, LLC | IGC-AD1-Active | — | ACTIVE NOT RECRUITING | 2026-11 | NCT05543681 |
| Acumen Pharmaceuticals | sabirnetug | — | ACTIVE NOT RECRUITING | 2026-10 | NCT06335173 |
| Biogen | Diranersen | — | ACTIVE NOT RECRUITING | 2026-03-11 | NCT05399888 |
| Spinogenix | SPG302 | — | ACTIVE NOT RECRUITING | 2025-12 | NCT06427668 |
| Inventage Lab., Inc. | Aricept Tablet | — | ACTIVE NOT RECRUITING | 2025-11-13 | NCT05345509 |
| Merry Life Biomedical Co., Ltd. | TML-6 | — | NOT YET RECRUITING | 2028-04-30 | NCT07612150 |
| Galimedix Therapeutics Inc | GAL-101 Salt | — | NOT YET RECRUITING | 2028-04-30 | NCT07789873 |
| Neurocrine Biosciences | NBI-1117567 | — | NOT YET RECRUITING | 2028-05 | NCT07832383 |
| BeyondBio Inc. | BEY2153 | — | NOT YET RECRUITING | 2028-07 | NCT06885567 |
| Vigonvita Life Sciences | Simenafil Hydrochloride Tablets 2.5 mg | — | NOT YET RECRUITING | 2028-09 | NCT07905352 |
| MTI Biotech Inc | 2-hydroxybenzylamine acetate | — | NOT YET RECRUITING | 2028-12-30 | NCT06432166 |
| Regeneration Biomedical, Inc. | RB-ADSC | — | NOT YET RECRUITING | 2029-02 | NCT07205601 |
| CellSight Technologies, Inc. | Drug: [18F]F-AraG (PET tracer) | — | NOT YET RECRUITING | 2029-09-16 | NCT07611357 |
| Ono Pharmaceutical Co., Ltd. | ONO-2020 | — | COMPLETED | 2026-07-31 | NCT06881836 |
| Eli Lilly | Mevidalen | — | COMPLETED | 2026-05-01 | NCT06538116 |
| PRInnovation GmbH | PRI-002 | — | COMPLETED | 2026-04-15 | NCT06182085 |
| Elixiron Immunotherapeutics Inc. | EI-1071 tablet, oral | — | COMPLETED | 2026-03-06 | NCT06745583 |
| NeuroTherapia, Inc. | NTRX-07 | — | COMPLETED | 2026-02-15 | NCT07058688 |
| AbbVie | ABBV-916 | — | COMPLETED | 2025-11-19 | NCT05291234 |
| Noah Pharmaceuticals, Inc. | MAR | — | COMPLETED | 2025-11-05 | NCT06597058 |
| HiDO Technologies | — | — | COMPLETED | 2025-09-30 | NCT06691256 |
| Beijing Joekai Biotechnology LLC | 50561 high dose | — | COMPLETED | 2025-08-22 | NCT05811442 |
| Inmune Bio, Inc. | XPro1595 | — | COMPLETED | 2025-05-12 | NCT05318976 |
| GemVax & Kael | GV1001 0.56mg | — | COMPLETED | 2025-04-03 | NCT05189210 |
| Bigespas LTD | DMB-I (Dimebon) | — | COMPLETED | 2025-01-13 | NCT06292351 |
| Treeway B.V. | TW001 | — | COMPLETED | 2024-12-30 | NCT05323812 |
| Eisai Inc. | Lecanemab 2.5 mg/kg | — | COMPLETED | 2024-12-10 | NCT01767311 |
| Lexeo Therapeutics | LX1001 | — | COMPLETED | 2024-11-07 | NCT03634007 |
| Applied Cognition | Dexmedetomidine | — | COMPLETED | 2024-09-13 | NCT07432997 |
| Alector Inc. | AL002 | — | COMPLETED | 2024-08-19 | NCT04592874 |
| AbbVie | ABBV-552 | — | COMPLETED | 2024-08-06 | NCT05771428 |
| Eli Lilly | LY3372689 | — | COMPLETED | 2024-07-09 | NCT05063539 |
| Supernus Pharmaceuticals, Inc. | SAGE-718 | — | COMPLETED | 2024-06-05 | NCT05619692 |
| Vaccinex Inc. | Pepinemab | — | COMPLETED | 2024-06-05 | NCT04381468 |
| Cognition Therapeutics | CT1812 | — | COMPLETED | 2024-05-29 | NCT03507790 |
| UCB Biopharma SRL | Bepranemab | — | COMPLETED | 2024-05-24 | NCT04867616 |
| Eisai Inc. | E2814 | — | COMPLETED | 2024-05-24 | NCT04971733 |
| IntelGenx Corp. | Montelukast buccal film | — | COMPLETED | 2024-03-13 | NCT03402503 |
| Eli Lilly | donanemab | — | COMPLETED | 2024-02-27 | NCT04640077 |
| Medesis Pharma SA | NanoLithium® NP03 | — | COMPLETED | 2024-01-23 | NCT05423522 |
| Vivoryon Therapeutics N.V. | PQ912 | — | COMPLETED | 2023-12-18 | NCT04498650 |
| Johnson & Johnson | Seltorexant | — | COMPLETED | 2023-11-10 | NCT05307692 |
| Cassava Sciences, Inc. | Simufilam 100 mg oral tablet | — | COMPLETED | 2023-11-09 | NCT04388254 |
| Longeveron Inc. | Allogeneic MSC | — | COMPLETED | 2023-09-29 | NCT05233774 |
| AC Immune SA | ACI-35.030 | — | COMPLETED | 2023-09-05 | NCT04445831 |
| Alzheon Inc. | ALZ-801 | — | COMPLETED | 2023-06-20 | NCT04693520 |
| NewAmsterdam Pharma | Obicetrapib | — | COMPLETED | 2023-05-09 | NCT05161715 |
| Cognition Therapeutics | CT1812 | — | COMPLETED | 2023-04-26 | NCT04735536 |
| Alzamend Neuro, Inc. | AL001 | — | COMPLETED | 2023-04-14 | NCT05363293 |
| Araclon Biotech S.L. | ABvac40 | — | COMPLETED | 2023-03-23 | NCT03461276 |
| T3D Therapeutics, Inc. | 15mg T3D-959 | — | COMPLETED | 2023-01-20 | NCT04251182 |
| Pharmazz, Inc. | Normal Saline along with standard treatment | — | COMPLETED | 2022-12-20 | NCT04052737 |
| Neurotrope Bioscience, Inc. | Bryostatin 1 | — | COMPLETED | 2022-11-16 | NCT04538066 |
| TrueBinding, Inc. | TB006 | — | COMPLETED | 2022-10-13 | NCT05074498 |
| LeonaBio | ATH-1017 | — | COMPLETED | 2022-05-20 | NCT04491006 |
| Roche | Crenezumab | — | COMPLETED | 2022-04-19 | NCT03977584 |
| Roche | Crenezumab | — | COMPLETED | 2022-03-22 | NCT01998841 |
| Medipost Co Ltd. | human umbilical cord blood derived mesenchymal stem cells | — | COMPLETED | 2022-03-18 | NCT03172117 |
| Annovis Bio Inc. | Posiphen | — | COMPLETED | 2021-12-10 | NCT02925650 |
| Mindful Diagnostics and Therapeutics, LLC | Bacillus of Calmette and Guerin (BCG) | — | COMPLETED | 2021-12-04 | NCT04449926 |
| Supernus Pharmaceuticals, Inc. | SAGE-718 | — | COMPLETED | 2021-09-28 | NCT04602624 |
| Eli Lilly | Zagotenemab | — | COMPLETED | 2021-08-23 | NCT03518073 |
| Annovis Bio Inc. | Posiphen | — | COMPLETED | 2021-08-16 | NCT04524351 |
| Roche | Semorinemab | — | COMPLETED | 2021-07-20 | NCT03828747 |
| Immungenetics AG | TEP | — | COMPLETED | 2021-07-12 | NCT03417986 |
| Photozig, Inc. | — | — | COMPLETED | 2021-05-30 | NCT04489303 |
| Photozig, Inc. | — | — | COMPLETED | 2021-05-30 | NCT04517877 |
| AbbVie | ABBV-8E12 | — | COMPLETED | 2021-03-30 | NCT02880956 |
| AriBio Co., Ltd. | AR1001 | — | COMPLETED | 2020-12-22 | NCT03625622 |
| Biohaven Pharmaceuticals, Inc. | troriluzole | — | COMPLETED | 2020-12-15 | NCT03605667 |
Showing 100 of 285 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Keymed Biosciences Co.Ltd | Alzheimer Disease (AD) | — | RECRUITING | 2026-12-30 | NCT06619613 |
| Eli Radiopharma | [18F]Flortaucipir Injection | — | RECRUITING | 2026-12-31 | NCT07580703 |
| Denali Therapeutics Inc. | DNL628 | — | RECRUITING | 2027-02 | NCT07328451 |
| Nuravax, Inc. | DUVAX 200 µg | — | RECRUITING | 2027-04-01 | NCT07142278 |
| Bristol-Myers Squibb | BMS-986446 | — | RECRUITING | 2027-06-17 | NCT07780383 |
| Eli Lilly | LY4006895 | — | RECRUITING | 2027-07 | NCT06657768 |
| Eli Lilly | LY3439539 | — | RECRUITING | 2027-08 | NCT07598370 |
| Eli Lilly | LY4405094 | — | RECRUITING | 2028-01 | NCT07787182 |
| Eli Lilly | LY3954068 | — | RECRUITING | 2028-07 | NCT06297590 |
| Eli Lilly | LY4405094 | — | RECRUITING | 2028-07 | NCT07787169 |
| Alnylam Pharmaceuticals | ALN-APP | — | RECRUITING | 2029-01-11 | NCT05231785 |
| Alnylam Pharmaceuticals | ALN-5288 | — | RECRUITING | 2030-03-06 | NCT07214727 |
| Denali Therapeutics Inc. | DNL921 | — | RECRUITING | 2030-04 | NCT07758595 |
| BnH Research | BnH-015B 5 mg | — | RECRUITING | 2026-04 | NCT06535308 |
| Luye Pharma Group Ltd. | LY03020 | — | RECRUITING | 2025-12-31 | NCT07230652 |
| Keymed Biosciences Co.Ltd | CM383 | — | RECRUITING | 2025-06-30 | NCT06412185 |
| ProMis Neurosciences, Inc | PMN310 | — | ACTIVE NOT RECRUITING | 2026-12 | NCT06750432 |
| Onward Health, Inc | — | — | ACTIVE NOT RECRUITING | 2026-12-28 | NCT06850870 |
| Roche | RO7812653 | — | ACTIVE NOT RECRUITING | 2027-03-31 | NCT07234942 |
| Therini Bio, Inc. | THN391 | — | ACTIVE NOT RECRUITING | 2027-03-31 | NCT06814730 |
| Lexeo Therapeutics | LX1001 | — | ACTIVE NOT RECRUITING | 2028-11 | NCT05400330 |
| Novartis | NIO752 | — | ACTIVE NOT RECRUITING | 2026-07-30 | NCT05469360 |
| Oligomerix, Inc | OLX-07010 Active | — | ACTIVE NOT RECRUITING | 2026-05-11 | NCT05696483 |
| Luye Pharma Group Ltd. | LY03020 | — | ACTIVE NOT RECRUITING | 2025-08-27 | NCT07292233 |
| Beijing Suncadia Pharmaceuticals Co., Ltd | SHR 3201 Injection | — | NOT YET RECRUITING | 2027-01 | NCT07889349 |
| Qilu Pharmaceutical Co., Ltd. | QLH2405 | — | NOT YET RECRUITING | 2027-03 | NCT07489599 |
| Pfizer | PF-08161842 | — | NOT YET RECRUITING | 2027-03-17 | NCT07897708 |
| Cenna Biosciences Inc. | 8M2D | — | NOT YET RECRUITING | 2027-09 | NCT07568041 |
| Eli Lilly | LY4560736 | — | NOT YET RECRUITING | 2028-07 | NCT07843459 |
| Regeneration Biomedical, Inc. | RB-ADSC | — | NOT YET RECRUITING | 2028-09 | NCT07373067 |
| Eisai Inc. | E2511 | — | NOT YET RECRUITING | 2030-05-06 | NCT07768592 |
| Acta Pharmaceuticals | GSM-779690T | — | NOT YET RECRUITING | 2026-08-15 | NCT07690228 |
| Nyree Penn | Diprivan (propofol), Astra-Zeneca | — | NOT YET RECRUITING | 2026-05-01 | NCT06644573 |
| Klotho Sciences Australia Pty Ltd. | Part 1 KS101 | — | NOT YET RECRUITING | 2026-04-01 | NCT07143331 |
| Luye Pharma Group Ltd. | LY03017 | — | NOT YET RECRUITING | 2025-10-31 | NCT06793995 |
| Luye Pharma Group Ltd. | LY03017 | — | NOT YET RECRUITING | 2025-10 | NCT06980207 |
| R3 Stem Cell | Amniotic and Umbilical Cord Tissue Procedure | — | NOT YET RECRUITING | 2024-03-20 | NCT03899298 |
| Perha Pharmaceuticals | Leucettinib-21 | — | COMPLETED | 2026-06-25 | NCT06206824 |
| Regeneration Biomedical, Inc. | RB-ADSC | — | COMPLETED | 2026-06-25 | NCT05667649 |
| Immunobrain Checkpoint | IBC-Ab002 | — | COMPLETED | 2025-12-16 | NCT05551741 |
| Nuravax, Inc. | AV-1959R (Abeta vaccine) | — | COMPLETED | 2025-12-01 | NCT06831812 |
| Neumora Therapeutics, Inc. | NMRA-323511 | — | COMPLETED | 2025-11-19 | NCT06546995 |
| Jiangsu Nhwa Pharmaceutical Co., Ltd. | NH280105- SAD | — | COMPLETED | 2025-11-13 | NCT06870058 |
| NeuroPro Therapeutics, Inc. | NPT 2042 (Reference formula/Formulation 1) | — | COMPLETED | 2025-11-04 | NCT07222878 |
| Allyx Therapeutics | BMS-984923 | — | COMPLETED | 2025-07-15 | NCT05804383 |
| Atridia Pty Ltd. | SHR-1707 injection | — | COMPLETED | 2025-07-08 | NCT06114745 |
| Merck | MK-2214 | — | COMPLETED | 2025-07-03 | NCT05466422 |
| AbbVie | ALIA-1758 | — | COMPLETED | 2025-04-22 | NCT06406348 |
| AbbVie | Emraclidine | — | COMPLETED | 2025-04-14 | NCT05644977 |
| Luye Pharma Group Ltd. | LY03020 | — | COMPLETED | 2025-02-13 | NCT06556966 |
| Alzinova AB | ALZ-101 | — | COMPLETED | 2025-01-27 | NCT05328115 |
| Vigil Neuroscience, Inc. | VG-3927 | — | COMPLETED | 2025-01-10 | NCT06343636 |
| Merck | MK-1708 | — | COMPLETED | 2024-12-10 | NCT06586606 |
| Eli Lilly | LY3372993 | — | COMPLETED | 2024-11-18 | NCT04451408 |
| Merck | MK-1167 | — | COMPLETED | 2024-09-23 | NCT06285240 |
| Acumen Pharmaceuticals | sabirnetug (ACU193) | — | COMPLETED | 2024-09-17 | NCT06511570 |
| Claritytek, Inc. | — | — | COMPLETED | 2024-08-20 | NCT05788848 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR-1707 | — | COMPLETED | 2024-05-18 | NCT05681819 |
| Edgewater Safety Systems, Inc. | — | — | COMPLETED | 2023-11-30 | NCT05153161 |
| SciNeuro | SNP318 (A) | — | COMPLETED | 2023-11-29 | NCT05792163 |
| Sinotau Pharmaceutical Group | — | — | COMPLETED | 2023-09-27 | NCT06151795 |
| H. Lundbeck A/S | Lu AF87908 | — | COMPLETED | 2023-07-19 | NCT04149860 |
| Roche | [18F]GTP1 | — | COMPLETED | 2023-06-27 | NCT04566003 |
| Acumen Pharmaceuticals | ACU193 | — | COMPLETED | 2023-06-12 | NCT04931459 |
| G2GBio, Inc. | GB-5001 | — | COMPLETED | 2023-06-02 | NCT05525780 |
| NeuroTherapia, Inc. | NTRX-07 | — | COMPLETED | 2023-05-31 | NCT06194552 |
| NeuroPro Therapeutics, Inc. | NPT 2042 (bumetanide analog) or Matching Placebo | — | COMPLETED | 2023-03-17 | NCT05503511 |
| Merck | Donepezil | — | COMPLETED | 2023-01-20 | NCT04730635 |
| Merck | Elpipodect | — | COMPLETED | 2023-01-10 | NCT05227118 |
| Cerecin | AC-OLE-01-VA | — | COMPLETED | 2022-12-22 | NCT05628636 |
| Virogenics, Inc. | CMS121 | — | COMPLETED | 2022-12-17 | NCT05318040 |
| Life Molecular Imaging GmbH | [18F]-PI2620 | — | COMPLETED | 2022-10-26 | NCT04715750 |
| Cerecin | AC-OLE-01-VA | — | COMPLETED | 2022-08-13 | NCT05408780 |
| Cognition Therapeutics | CT1812 | — | COMPLETED | 2022-06-01 | NCT05248672 |
| Merck | MK-1942 | — | COMPLETED | 2022-05-18 | NCT04308304 |
| AlzeCure Pharma | ACD856 | — | COMPLETED | 2022-05-16 | NCT05077501 |
| Ionis Pharmaceuticals, Inc. | IONIS MAPTRx | — | COMPLETED | 2022-05-12 | NCT03186989 |
| TrueBinding, Inc. | TB006 | — | COMPLETED | 2022-05-03 | NCT04920786 |
| reMYND | REM0046127 | — | COMPLETED | 2022-04-01 | NCT04672135 |
| Atridia Pty Ltd. | SHR-1707 | — | COMPLETED | 2022-03-21 | NCT04745104 |
| AlzeCure Pharma | ACD856 | — | COMPLETED | 2022-02-22 | NCT05077631 |
| Cognition Therapeutics | 300 mg [C14] CT1812 | — | COMPLETED | 2022-01-17 | NCT05225389 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | SHR-1707 | — | COMPLETED | 2022-01-13 | NCT04973189 |
| BeyondBio Inc. | BEY2153 | — | COMPLETED | 2021-11-23 | NCT04476303 |
| Neuronascent, Inc. | NNI-362 | — | COMPLETED | 2021-07-31 | NCT04074837 |
| Inmune Bio, Inc. | XPro1595 | — | COMPLETED | 2021-06-30 | NCT03943264 |
| Alector Inc. | AL003 | — | COMPLETED | 2021-05-06 | NCT03822208 |
| AZTherapies, Inc. | ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen) | — | COMPLETED | 2021-01-18 | NCT04570644 |
| Roche | — | — | COMPLETED | 2020-10-09 | NCT04394845 |
| Longeveron Inc. | Longeveron Mesenchymal Stem Cells | — | COMPLETED | 2020-09 | NCT02600130 |
| Alector Inc. | AL002 | — | COMPLETED | 2020-08-03 | NCT03635047 |
| Roche | RO7126209 | — | COMPLETED | 2020-07-17 | NCT04023994 |
| Cerecin | Tricaprilin | — | COMPLETED | 2020-04-02 | NCT03971123 |
| Cerecin | Tricaprilin | — | COMPLETED | 2020-03-26 | NCT04268953 |
| Biogen | BIIB076 | — | COMPLETED | 2020-03-03 | NCT03056729 |
| Abrexa Pharmaceuticals, Inc. | J147 | — | COMPLETED | 2020-02-01 | NCT03838185 |
| Johnson & Johnson | JNJ-63733657 | — | COMPLETED | 2019-12-16 | NCT03375697 |
| Denali Therapeutics Inc. | DNL747 | — | COMPLETED | 2019-12-05 | NCT03757325 |
| Five Eleven Pharma, Inc. | [18F]P16-129 | — | COMPLETED | 2019-11-02 | NCT03902548 |
| Theranexus | THN 201 | — | COMPLETED | 2019-10-20 | NCT03698695 |
Novel Alzheimer's Disease Drugs by Company (New molecular entities)
6 companies have an FDA-approved novel drug for Alzheimer's Disease.
Reformulations (4 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Alzheimer's Disease Drug Targets
Molecular targets of approved and investigational Alzheimer's Disease drugs — 10 targets tracked.
Generic Drugs (1 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs